IGHE and allergic disease: With a higher affinity for IgE than omalizumab, IgETRAP better suppresses mast cell degranulation and free IgE serum levels (Fig. 2), demonstrating IgETRAP’s potential as a safer and more potent therapeutic option for treating IgE-mediated allergic diseases.